An evaluation of meropenem/vaborbactam for the treatment of nosocomial pneumonia

References

• Haque M, Sartelli M, McKimm J, et al. Health care-associated infections – an overview. Infect Drug Resist. 2018;11:2321–2333.
   PubMed Web of Science ®Google Scholar
• Jones R. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51(S1):S81–87.
   PubMedGoogle Scholar
• CDC’s Antibiotic-Resistant Germs: New Threats. Centers for disease control and prevention. Atlanta, GA: 2020. Available at: https://www.cdc.gov/drugresistance/biggest-threats.html [Last accessed 2020 Jul 30]
   Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of america and the american thoracic society. Clin Infect Dis. 2016;63(5):e61–111.
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(11):e01443–17. .
   PubMed Web of Science ®Google Scholar
• Lee Y, Kim J, Trinh S. Meropenem–vaborbactam (vabomereTM): another option for carbapenem-resistant enterobacteriaceae. P T. 2019;44(3):110–113.
   Google Scholar
• US Food and Drug Administration. Drug approval package. Avycaz® (ceftazidime/avibactam) intravenous injection. 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206494s005,s006lbl.pdf [Last accessed 2020 Jul 30].
   Google Scholar
• US Food and Drug Administration. Drug approval package. Vabomere® (meropenem/vaborbactam) intravenous injection. 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209776lbl.pdf [Last accessed 2020 Jul 30].
   Google Scholar
• US Food and Drug Administration. Drug approval package. RecarbrioTM (imipenem, cilastatin, relebactam) intravenous injection. 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf [Last accessed 2020 Jul 30].
   Google Scholar
• US Food and Drug Administration. Drug approval package. Zerbaxa® (ceftolozane/tazobactam) intravenous injection. 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf [Last accessed 2020 Jul 30].
   Google Scholar
• van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis. 2016;63:234–241.
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61(8):e00883–17.
   Google Scholar
• van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae. Clin Infect Dis. 2018;66:163–171.
   PubMed Web of Science ®Google Scholar
• Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2016;63:1615–1618.
   PubMed Web of Science ®Google Scholar
• Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285–295.
   PubMed Web of Science ®Google Scholar
• Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother. 2017;72:2616–2626.
   PubMed Web of Science ®Google Scholar
• Lucasti C, Vasile L, Sandesc D, et al. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2016;60:6234–6243.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Drug approval package. ZemdriTM (plazomicin) intravenous injection. 2018. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210303orig1s000lbl.pdf [Last accessed 2020 Oct 13].
   Google Scholar
• US Food and Drug Administration. Drug approval package. Fetroja® (cefiderocol) intravenous injection. 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209445s000lbl.pdf [Last accessed 2020 Oct 13].
   Google Scholar
• Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med. 2019;380:729–740.
   PubMed Web of Science ®Google Scholar
• Portsmouth S, Van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18(12):1319–1328.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2020. published online ahead of print October 12. 10.1016/S1473-3099(20)30731-3.
   Web of Science ®Google Scholar
• Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2020. published online ahead of print October 12. 10.1016/S1473-3099(20)30796-9.
   Web of Science ®Google Scholar
• Doi Y. Penicillins and Beta-Lactamase Inhibitors. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Philadelphia, PA: Elsevier, Inc; 2020. p. 41–51.
   Google Scholar
• Rubino CM, Bhavnani SM, Loutit JS, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of vaborbactam and meropenem alone and in combination following single and multiple doses in healthy adult subjects. Antimicrob Agents Chemother. 2018;62(4):e02228–17.
   Web of Science ®Google Scholar
• Griffith DC, Loutit JS, Morgan EE, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of the β-lactamase inhibitor vaborbactam (RPX7009) in healthy adult subjects. Antimicrob Agents Chemother. 2016;60:6326–6332.
   PubMed Web of Science ®Google Scholar
• Grande Roche KK. Clinical microbiology review. meropenem-vaborbactam. nda#209776. remplex pharmaceuticals. division of anti-infective products. Center Drug Evaluation Res. US Food and Drug Administration. 2017.
   Google Scholar
• Ambrose PG, Bhavnani SM, Grosse EJE, et al. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! Clin Infect Dis. 2010;51:S103–S110.
   PubMed Web of Science ®Google Scholar
• Wenzler E, Gotfried MH, Loutit JS, et al. Meropenem-rpx7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects. Antimicrob Agents Chemother. 2015;59:7232–7239.
   PubMed Web of Science ®Google Scholar
• Honeybourne D. Antibiotic penetration into lung tissues. Thorax. 1994;49:104–106.
   PubMed Web of Science ®Google Scholar
• Jorgensen SCJ, Rybak MJ. Meropenem and vaborbactam: stepping up the battle against carbapenem-resistant enterobacteriaceae. Pharmacotherapy. 2018;38:444–461.
   PubMed Web of Science ®Google Scholar
• Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. Clin Microbiol Rev. 2010;23:160–201.
   PubMed Web of Science ®Google Scholar
• Livermore DM. Determinants of the activity of β-lactamase inhibitor combinations. J Antimicrob Chemother. 1993;31:9–21.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Martínez J-M, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53:4783–4788.
   PubMed Web of Science ®Google Scholar
• De Oliveira DMP, Forde BM, Kidd TJ, et al. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev. 2020;33:e00181–19.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Huband MD, Mendes RE, et al. Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, kpc-producing, multidrug-resistant, and extensively drug-resistant enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(9):e00567–17.
   Web of Science ®Google Scholar
• Castanheira M, Rhomberg PR, Flamm RK, et al. Effect of the β-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing enterobacteriaceae. Antimicrob Agents Chemother. 2016;60:5454–5458.
   PubMed Web of Science ®Google Scholar
• Hackel MA, Lomovskaya O, Dudley MN, et al. In vitro activity of meropenem-vaborbactam against clinical isolates of kpc-positive enterobacteriaceae. Antimicrob Agents Chemother. 2018;62(1):e01904–17.
   PubMed Web of Science ®Google Scholar
• Lapuebla A, Abdallah M, Olafisoye O, et al. Activity of meropenem combined with rpx7009, a novel β-lactamase inhibitor, against gram-negative clinical isolates in New York City. Antimicrob Agents Chemother. 2015;59:4856–4860.
   PubMed Web of Science ®Google Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing 27th information supplement. CLSI document M100-S27. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
   Google Scholar
• EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0. Växjö, Sweden: European Committee on Antimicrobial Susceptibility Testing; 2020.
   Google Scholar
• Patel T, Kaye K, Krishnan J, et al. Comparative in vitro activity of meropenem/vaborbactam and meropenem against a collection of real-world isolates of pseudomonas aeruginosa. Open Forum Infect Dis. 2019;6(Suppl 2):S251.
   Google Scholar
• Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the tango i randomized clinical trial. JAMA. 2018;319:788–799.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem–vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the tango ii randomized clinical trial. Infect Dis Ther. 2018;7:439–455.
   PubMed Web of Science ®Google Scholar
• Ackley R, Roshdy D, Meredith J, et al. Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant enterobacteriaceae infections. Antimicrob Agents Chemother. 2020;64(5):e02313–19.
   Web of Science ®Google Scholar
• Alosaimy S, Jorgensen SCJ, Lagnf AM, et al. Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections. Open Forum Infect Dis. 2020;7:ofaa051.
   PubMed Web of Science ®Google Scholar
• Shields RK, McCreary EK, Marini RV, et al. Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2020;71:667–671.
   PubMed Web of Science ®Google Scholar